Kore Private Wealth’s BridgeBio Pharma BBIO Stock Holding History

Kore Private Wealth’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$390K	Buy	39,243 +1,000	+3%	+$10.4K	0.07%	156
2022 Q2	$347K	Hold	38,243	–	–	0.05%	196
2022 Q1	$388K	Buy	38,243 +4,000	+12%	+$41.1K	0.05%	203
2021 Q4	$571K	Buy	34,243 +4,898	+17%	+$207K	0.07%	156
2021 Q3	$1.38M	Hold	29,345	–	–	0.14%	120
2021 Q2	$1.79M	Buy	29,345 +602	+2%	+$34.4K	0.2%	88
2021 Q1	$1.77M	Hold	28,743	–	–	0.24%	74
2020 Q4	$2.04M	Buy	28,743 +500	+2%	+$24.1K	0.31%	60
2020 Q3	$1.06M	Hold	28,243	–	–	0.2%	80
2020 Q2	$921K	Hold	28,243	–	–	0.19%	86
2020 Q1	$819K	Buy	28,243 +22,243	+371%	+$690K	0.2%	84
2019 Q4	$210K	Buy	+6,000	New	+$166K	0.04%	234

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Kore Private Wealth's BBIO Position: Q3 2022 in Review

Kore Private Wealth increased its BridgeBio Pharma (BBIO) stake by 2.6% in Q3 2022, buying an estimated $10.4K and bringing the position to 39,243 shares worth $390K. The position accounts for 0.07% of the portfolio, ranked #156.

Kore Private Wealth first reported a position in BBIO in Q4 2019 and has held it in 12 quarters since. The position peaked at $2.04M in Q4 2020. 181 funds tracked by Wall St. Rank hold BBIO as of Q3 2022.

Kore Private Wealth held 39,243 shares of BridgeBio Pharma worth $390K as of Q3 2022.
Kore Private Wealth bought 1,000 BridgeBio Pharma shares in Q3 2022, an estimated $10.4K.
BridgeBio Pharma made up 0.07% of Kore Private Wealth's portfolio in Q3 2022, its #156 holding.
Kore Private Wealth first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 12 quarters since.
Kore Private Wealth's BridgeBio Pharma position peaked at $2.04M in Q4 2020.
181 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2022.

Based on Kore Private Wealth's 13F filing for Q3 2022, filed 14 Nov 2022.